Solstice Oncology
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
$225MSeries A
ParticipantF
Forbion
Activity from announced rounds
Activity in this selectionSeries A
Forbion is an investment firm whose official portfolio and financing news identify CellCentric, Sling and Solstice.
Recorded funding activity
Sling develops an oral medicine for thyroid eye disease. Solstice advances an engineered cancer-immunotherapy antibody, while RQ Bio develops preventive antibodies for vulnerable patients facing influenza. These are separate clinical programs and company financings.
Sources
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 3 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $550M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionRQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedSlate Medicines
Advancing next-generation therapeutics for migraine and other headache disorders
$130MSeries A
Role not disclosedCorsera Health
Develops preventive RNAi medicines for cardiovascular disease prediction and prevention
$80MSeries A
Role not disclosed